infliximab Archives

Celltrion positive phase III results for infliximab biobetter Remsima SC®

by Bioblast Editor | Mar 3, 2023 | Biosimilars updates

Celltrion Healthcare presented its positive phase III results for its infliximab biobetter Remsima SC® as a sub-cutaneous maintenance therapy for patients with IBD. Remsima SC® (CT-P13 SC) is Celltrion’s subcutaneous re-formulation of Johnson & Johnson’s...

Study finds nonmedical switching policy did not negatively impact patients

by Bioblast Editor | Mar 1, 2023 | Biosimilars updates

A new study published in Gastroenterology Research and Practice has found that British Columbia’s 2019 ‘Biosimilars Initiative’ was not associated with harmful impacts on medications and health services use. The Initiative required IBD patients to switch from Johnson...

Organon publishes financial results for Q4 and full year ended December 2022

by Bioblast Editor | Feb 16, 2023 | Biosimilars updates

Organon published its results for Q4 and full year ended 31 December 2022, reporting a second consecutive year of double-digit revenue growth in biosimilars. Organon reported that this growth was primarily drive by double-digit growth from Renflexis® (biosimilar to...

Celltrion submits BLA for CT-P13 SC (subcutaneous biosimilar infliximab)

by Bioblast Editor | Dec 22, 2022 | Biosimilars updates

Celltrion announced that it has submitted a BLA for CT-P13 SC (subcutaneous biosimilar infliximab) with the FDA. CT-P13 is the first and only known infliximab to have both intravenous and subcutaneous formulations.

J&J report a 53% decrease in Remicade® exports

by Bioblast Editor | Jul 19, 2022 | Biosimilars updates

Johnson & Johnson reported a 53% YoY decrease in exports of Remicade® (infliximab) from the US suggesting a very significant decline in global Remicade sales since the first approved biosimilar in 2013.